Level of High-Sensitivity C-Reactive Protein Assay to Evaluate Risk in Follow-Up Patients with Acute Coronary Syndrome
Introduction: Among currently recognized inflammatory markers numbers of considerations favor high-sensitivity C-reactive
protein (Hs-CRP) as a potentially useful predictor of prevalence and incidence of cardiovascular diseases. Clinical interest
in these markers has also focused on their potential utility in predicting future cardiovascular events and thereby in patient’s
Purpose of study: The purpose of the study was to determine the mean level of Hs-CRP assay in patients of acute coronary
syndromes and corelation of Hs-CRP with two or more major risk factors and to correlate the level of Hs-CRP and cardiac
events in patients of acute coronary syndromes during follow-up of a specified period of 6 months.
Materials and Methods: Present study had been carried out in the Department of Medicine, Gajra Raja Medical College
and associated Hospital, Gwalior, Madhya Pradesh, India, from January 2004 to September 2005. This was a prospective
observational study. The targeted populations were 30 cases with acute coronary syndromes of both sexes.
Results: The study was statistically insignificant in reference to various major cardiac events compared to various levels of HsCRP. ST elevation myocardial infarction (MI) was the most prevalent acute coronary syndrome. Most of the risk factors show
their association with the moderate risk level of Hs-CRP, i.e., 1.0–3.0 mg/L, followed by high-risk levels, i.e., >3.0 mg/L, followed
by low-risk levels, i.e., <1.0 mg/L. Post MI/angina was the major cardiac event that highest number of patients developed,
during the follow-up period of 6 months.
Conclusion: No statistically significant association of various risk factors with Hs-CRP was observed in patients of acute
coronary syndromes. No statistically significant association of Hs-CRP levels with major cardiac events was appreciable in
patients of acute coronary syndrome in a follow-up period of 6 months.
C-reactive protein: Clinical and epidemiological perspectives. Cardiol Res
2. Panteghini M. Role and importance of biochemical markers in clinical
cardiology. Euro Heart J 2004;25:1187-96.
3. Heeschen C. Predictive value of C-reactive protein and troponin T in
patients with unstable angina: A comparative analysis. J A Coll Cardiol
4. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P,
et al. N-terminal pro-brain natriuretic peptide and other risk markers for
the separate prediction of mortality and subsequent myocardial infarction
in patients with unstable coronary artery disease: A Global utilization of
strategies to open occluded arteries (GUSTO)-IV substudy. Circulation
5. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA,
et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in
asymptomatic adults: Executive summary: A report of the American college
of cardiology foundation/American heart association task force on practice
guidelines. Circulation 2010;122:2748-64.
6. Araujo JP, Lourenc P, Zevedo A, Friores F, Rocha-Goncalves F, Ferreira A,
et al. Prognostic value of high-sensitivity C-reactive protein in heart failure:
A systematic review. J Cardiac Fail 2009;15:256-66.
7. Alyan O, Metin F, Kacmaz F, Ozdemir O, Maden O, Topaloglu S, et al.
High levels of high sensitivity C-reactive protein predict the progression
of chronic rheumatic mitral stenosis. J Thromb Thrombolysis
8. Sharma A, Chomayil Y, Karim FA, Parambil VP. Incidence and risk factors
of acute coronary syndrome in younger age groups. Int J Emerg Med
2015;8 Suppl 1:P4.
9. Singh SS, Paul SK, Pal R, Thatkar PV. Acute coronary syndrome-related
mortality audit in a teaching hospital at Port Blair. India J Fam Med Prim
10. Ohira T, Iso H. Cardiovascular disease epidemiology in Asia: An overview.
Circ J 2013;77:1646-52.
11. Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, et al.
Treatment and outcomes of acute coronary syndromes in India (CREATE):
A prospective analysis of registry data. Lancet 2008;371:1435-42.
12. Hajar R. Diabetes as coronary artery disease risk equivalent: A Historical
perspective. Heart Views 2017;18:34-7.
13. Cervellin G, Rastelli G. The clinics of acute coronary syndrome. Ann Transl
14. Karki P, Agrawaal KK, Lamsal M, Shrestha NR. Predicting outcomes
in acute coronary syndrome using biochemical markers. Indian Heart J
15. Stone PH, Thompson B, Anderson HV, Kronenberg MW, Gibson RS,
Rogers WJ, et al. Influence of race, sex, and age on management of unstable
angina and non-Q-wave myocardial infarction: The TIMI III registry.
16. Ridker PM. Clinical application of C-reactive protein for cardiovascular
disease detection and prevention. Circulation 2003;107:363-9.
17. Calabró P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated
C-reactive protein production by human coronary artery smooth muscle
cells. Circulation 2003;108:1930-2.
18. Adukauskienė D, Čiginskienė A, Adukauskaitė A, Pentiokinienė D,
Šlapikas R, Čeponienė I, et al. Clinical relevance of high sensitivity
C-reactive protein in cardiology. Medicina (Kaunas) 2016;52:1-0.
19. Wilson PW, Pencina M, Jacques P, Selhub J, D’Agostino R Sr,
O’Donnell CJ, et al. C-reactive protein and reclassification of
cardiovascular risk in the Framingham heart study. Circ Cardiovasc Qual